Day: June 19, 2021

New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed

New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed

VANCOUVER, British Columbia, June 19, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has commenced the development of a next-generation psychedelic drug formulation for the purpose of mitigating neurological damage that results from ischemic strokes. Akome’s next generation psychedelic drug formulation for the mitigation of neurological damage resulting from ischemic strokes, also known as AKO001, is comprised of the psychedelic compound N,N-dimethyltryptamine (DMT) and a specific plant bioactive which, when combined together, are believed to work in a complementary and mitigating manner when provided to individuals immediately following their ischemic stroke. A provisional matter...

Continue reading

Toga Limited’s Majority-Owned Subsidiary, Eostre Berhad is Appointed as the Exclusive Worldwide Distributor for Shenzhen Shengquan Biotechnology Co Ltd

Toga Limited’s Majority-Owned Subsidiary, Eostre Berhad is Appointed as the Exclusive Worldwide Distributor for Shenzhen Shengquan Biotechnology Co Ltd

PETALING JAYA, Malaysia, June 18, 2021 (GLOBE NEWSWIRE) — Eostre Berhad, a majority-owned subsidiary of Toga Limited (OTC: TOGL), has been officially appointed by China’s Shenzhen Shengquan Biotechnology Co., Ltd., as its exclusive worldwide distributor for its product, the “H2O Energy Bottle”. Eostre is now tasked with developing a world-wide market for the “H2O energy bottles”. “We are pleased to establish this collaboration between Shenzhen Shengquan Biotechnology and Eostre. This collaboration will further grow Eostre’s product range and customer base globally,” said Eostre Berhad General Manager, Ms. Low Kah Fong. “We anticipate both companies will jointly expand the awareness and demand for the H2O energy bottle. This is also seen as being in line with Eostre’s vision of becoming an international brand with world-leading...

Continue reading

ISS and Glass Lewis recommend Fortuna and Roxgold shareholders to vote in favor of proposed business combination

ISS and Glass Lewis recommend Fortuna and Roxgold shareholders to vote in favor of proposed business combination

ISS and Glass Lewis both state that the proposed arrangement is in the best interest of Fortuna and Roxgold shareholders The deadline to vote is prior to 9:00 a.m. Pacific time on June 24, 2021 for both Fortuna and Roxgold shareholders VANCOUVER, British Columbia, June 18, 2021 (GLOBE NEWSWIRE) — Fortuna Silver Mines Inc. (NYSE: FSM | TSX: FVI) and Roxgold Inc. (TSX: ROXG | OTCQX: ROGFF) are pleased to announce that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”), two leading proxy advisory firms who provide independent voting recommendations to institutional investors, have recommended that both Fortuna and Roxgold shareholders vote “FOR” the companies´ respective resolutions in connection with the proposed business combination (the “Transaction”), between Fortuna and Roxgold...

Continue reading

Biophytis announces new convertible bond financing for up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million

Biophytis announces new convertible bond financing for up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million

PARIS and Cambridge, Mass., June 19, 2021 (GLOBE NEWSWIRE) — Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces a new line of financing through Bonds Redeemable in Cash and New and Existing Shares (ORNANE) with Atlas, a specialized investment fund based in New York (United States), for €32 million (the “2021 Atlas Contract”). This line of financing will be used for further clinical development of Sarconeos (BIO101) in sarcopenia following our SARA phase 2 results and for...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.